Celyad Oncology SA (CYAD) Stock Analyst Ratings
NASDAQ:CYAD - Nasdaq - US1512052002 - ADR - Currency: USD
ChartMill assigns a Buy % Consensus number of 40% to CYAD. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 0.48. This target is 1.41% above the current price.
CYAD was analyzed by 10 analysts. The buy percentage consensus is at 40. So analysts seem to be rather negative about CYAD.
In the previous month the buy percentage consensus was at a similar level.
CYAD was analyzed by 10 analysts. More opinions would make the average more meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2022-01-11 | Wells Fargo | Maintains | Overweight |